Clinical trial
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
NCT00275301 · University of Minnesota, Other · Completed
Key facts
| NCT number | NCT00275301 |
|---|---|
| Title | PET Imaging and Olanzapine Treatment in Borderline Personality Disorder |
| Official title | Brain Correlates of Olanzapine Treatment Response in BPD |
| Lead sponsor | University of Minnesota, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder |
| Intervention type | Drug |
| Interventions | olanzapine |
| Enrollment | 19 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jan 11, 2006 |
| Last update posted | May 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: